Ropes & Gray Named The American Lawyer’s “Law Firm of the Year” and Ranked #1 on the A-List in the U.S. and UK

In 2022, Ropes & Gray was named as The American Lawyer’s “Law Firm of the Year” and ranked #1 on the prestigious “A-List” in both the U.S. and the UK, an unprecedented achievement for a law firm.

The “Law Firm of the Year” recognizes one firm that The American Lawyer said “netted big wins but also showed a commitment to pro bono, diversity, and innovation in how legal services are delivered.” Ropes & Gray’s market-leading practices led historic matters across core industries—private equity, asset management, health care, life sciences, technology and real estate—including deals and fund closings, as well as restructurings, complex compliance issues, investigations, litigation and enforcement matters. 

The A-List is one of the legal industry’s most prestigious honors because it is based on economic as well cultural factors: financial performance, pro bono commitment and racial and gender diversity. Earning a top spot shows that a firm excels in its commitment to its clients, lawyers and communities. According to the UK ranking, Ropes & Gray “achieved a perfect score on its revenue per lawyer metric, as well as the highest score of the table on gender diversity.” In the US, “the data for Ropes & Gray showed a 17-point gain on the A-List’s diversity metric, easily the largest gain for firms in the top 20 of the annual rankings,” and the publication noted gains in associate satisfaction, among other increases.

In 2022, Ropes & Gray also won The American Lawyer’s “Corporate Practice of the Year – Health Care & Pharmaceuticals” for excellence advising clients on the full spectrum of complex health care and life sciences matters across transactions, licensing, regulatory, litigation, investigations and enforcement. Ropes & Gray’s life sciences and healthcare teams delivered exceptional results for clients at a critical time, helping COVID-19 vaccine manufacturers bring the vaccines to market; guiding hospitals and public and private companies in their continued pandemic response; and steering innovative, groundbreaking large- and mid-cap deals and complex licensing matters for clients around the globe.

Cookie Settings